Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Clin Radiol. 2024 Jun;79(6):436-445. doi: 10.1016/j.crad.2024.02.008. Epub 2024 Mar 16.
Our main goal of this meta-analytical analysis was to evaluate the diagnostic effectiveness of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) against multiparametric magnetic resonance imaging (mpMRI) in the context of identifying biochemical recurrence in patients with prostate cancer (PCa).
A thorough search covering articles published until March 2023 was carried out across major databases such as PubMed, Embase, and Web of Science. Studies examining the direct comparison of PSMA PET/CT and mpMRI in patients with PCa suffering biochemical recurrence were included in the inclusion criteria. Using the renowned Quality Assessment of Diagnostic Performance Studies-2 technique, each study's methodological rigor was assessed.
We analyzed data from six eligible studies involving 290 patients in total. The combined data showed that for PSMA PET/CT and mpMRI, respectively, the pooled overall detection rates for recurrent PCa after definitive treatment were 0.69 (95% confidence interval [CI]: 0.45-0.89) and 0.70 (95% CI: 0.44-0.91). The detection rates for local recurrence were specifically 0.52 (95% CI: 0.39-0.65) and 0.62 (95% CI: 0.31-0.89), while they were 0.50 (95% CI: 0.26-0.74) and 0.32 (95% CI: 0.18-0.48) for lymph node metastasis. Notably, there was no discernible difference between the two imaging modalities in terms of the overall detection rate (P = 0.95). The detection rates for local recurrence and lymph node metastasis did not differ statistically significantly (P = 0.55, 0.23).
The performance of PSMA PET/CT and mpMRI in identifying biochemical recurrence in PCa appears to be comparable. However, the meta-analysis' findings came from research with modest sample sizes. In this context, more extensive research should be conducted in the future.
本荟萃分析的主要目的是评估前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)/计算机断层扫描(CT)在识别前列腺癌(PCa)患者生化复发方面相对于多参数磁共振成像(mpMRI)的诊断效果。
通过全面搜索 PubMed、Embase 和 Web of Science 等主要数据库,对截至 2023 年 3 月发表的文章进行了搜索。纳入标准包括研究 PSMA PET/CT 和 mpMRI 在经历生化复发的 PCa 患者中的直接比较。使用著名的诊断性能研究质量评估-2 技术,评估了每个研究的方法学严谨性。
我们分析了 6 项符合条件的研究,共涉及 290 名患者的数据。综合数据显示,对于 PSMA PET/CT 和 mpMRI,分别为 0.69(95%置信区间:0.45-0.89)和 0.70(95%置信区间:0.44-0.91),用于检测经过确定性治疗后复发性 PCa 的总体检出率。局部复发的检出率分别为 0.52(95%置信区间:0.39-0.65)和 0.62(95%置信区间:0.31-0.89),而淋巴结转移的检出率分别为 0.50(95%置信区间:0.26-0.74)和 0.32(95%置信区间:0.18-0.48)。值得注意的是,两种成像方式在总体检出率方面没有明显差异(P=0.95)。局部复发和淋巴结转移的检出率在统计学上没有显著差异(P=0.55,0.23)。
PSMA PET/CT 和 mpMRI 在识别 PCa 生化复发方面的表现似乎相当。然而,荟萃分析的结果来自样本量较小的研究。在这种情况下,未来应该进行更广泛的研究。